Pharmaceutical Composition Comprising Eliglustat

Patent No. EP3664798 (titled "Pharmaceutical Composition Comprising Eliglustat") was filed by Amneal Pharmaceuticals on Aug 6, 2018. The application was issued on Jun 17, 2020.

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

Date
Description

Get instant alerts for new documents

Nov 11, 2025
Transmission of the certificate for a European patent pursuant to Rule 74 EPC
Oct 2, 2025
Decision to grant a European patent
Sep 24, 2025
(Electronic) Receipt
Sep 24, 2025
Filing of the translations of the claims
Sep 24, 2025
French translation of claims
Sep 24, 2025
German translation of the claims
Jun 5, 2025
Communication of the registration of a transfer or change of name and/or address
May 28, 2025
(Electronic) Receipt
May 28, 2025
Annexes in respect of a client data request
May 28, 2025
Annexes in respect of a client data request
May 28, 2025
Letter accompanying subsequently filed items
May 28, 2025
Submission concerning a transfer of rights (applicant)
May 26, 2025
Annex to the communication about intention to grant a European patent
May 26, 2025
Bibliographic data of the European patent application
May 26, 2025
Communication about intention to grant a European patent
May 26, 2025
Intention to grant (signatures)
May 26, 2025
Text intended for grant (clean copy)
May 26, 2025
Text intended for grant (version for approval)
Apr 11, 2025
(Electronic) Receipt
Apr 11, 2025
Letter accompanying subsequently filed items
Apr 11, 2025
Request for correction/amendment of the text proposed for grant sent from 01.04.2012
Dec 17, 2024
Annex to the communication about intention to grant a European patent
Dec 17, 2024
Bibliographic data of the European patent application
Dec 17, 2024
Communication about intention to grant a European patent
Dec 17, 2024
Intention to grant (signatures)
Dec 17, 2024
Text intended for grant (clean copy)
Dec 17, 2024
Text intended for grant (version for approval)
Jul 19, 2024
(Electronic) Receipt
Jul 19, 2024
Amended claims with annotations
Jul 19, 2024
Amended description with annotations
Jul 19, 2024
Claims
Jul 19, 2024
Description
Jul 19, 2024
Letter accompanying subsequently filed items
Jul 19, 2024
Reply to communication from the Examining Division
Mar 21, 2024
Annex to the communication
Mar 21, 2024
Communication from the Examining Division
Mar 14, 2024
Examination started
Feb 14, 2022
Communication of the registration of a transfer or change of name and/or address
Feb 14, 2022
Communication of the registration of a transfer or change of name and/or address
Feb 8, 2022
(Electronic) Receipt
Feb 8, 2022
Letter accompanying subsequently filed items
Feb 8, 2022
Submission concerning change of applicant's address
Jan 14, 2022
(Electronic) Receipt
Jan 14, 2022
Letter accompanying subsequently filed items
Jan 14, 2022
Statement of non-availability of priority search results
Nov 17, 2021
Invitation to file a copy of search results(priority)
Nov 8, 2021
(Electronic) Receipt
Nov 8, 2021
Amended claims filed after receipt of (European) search report
Nov 8, 2021
Amended claims with annotations
Nov 8, 2021
Amendments received before examination
Nov 8, 2021
Annex
Nov 8, 2021
Letter accompanying subsequently filed items
Apr 28, 2021
Invitation to declare maintenance of the application and to correct deficiencies in the Written Opinion/amend application
Apr 7, 2021
Communication regarding the transmission of the European search report
Apr 7, 2021
European search opinion
Apr 7, 2021
Information on Search Strategy
Apr 7, 2021
Supplementary European search report
Mar 25, 2021
Search started
Oct 12, 2020
(Electronic) Receipt
Oct 12, 2020
Amended claims filed after receipt of (European) search report
Oct 12, 2020
Amended claims with annotations
Oct 12, 2020
Amendments received before examination
Oct 12, 2020
Letter accompanying subsequently filed items
May 20, 2020
Notification on forthcoming publication of bibliographic data
Apr 3, 2020
Communication regarding possible amendment of the application/payment of claims fee
Mar 17, 2020
Communication to designated inventor
Mar 17, 2020
Communication to designated inventor
Mar 17, 2020
Communication to designated inventor
Mar 17, 2020
Communication to designated inventor
Mar 11, 2020
Notification of the recording of a change
Mar 10, 2020
(Electronic) Receipt
Mar 10, 2020
Annex
Mar 10, 2020
Letter accompanying subsequently filed items
Mar 10, 2020
Matter concerning the application
Mar 6, 2020
(Electronic) Receipt
Mar 6, 2020
Request for entry into the European phase
Feb 26, 2020
Copy of the international preliminary report on patentability
Dec 20, 2019
Information on entry into European phase
Mar 5, 2019
Priority document (electronically transmitted)
Feb 14, 2019
Copy of the international search report
Feb 14, 2019
Published international application - A1

EP3664798

AMNEAL PHARMACEUTICALS

Application Number: EP18845286A
Filing Date: Aug 6, 2018
Status: Intended To Grant; May 25, 2025
Publication Date: Jun 17, 2020
External Links: Slate, Register , Google Patents

IP Verse

Pharmaceutical Composition Comprising Eliglustat

Patent Summary

Patent Family

Dossier Documents

EP3664798